Shares of Inovio Pharmaceuticals INO decreased in after-market trading after the company reported Q1 results.
Earnings per share decreased 3.85% over the past year to ($0.27), which missed the estimate of ($0.18).
Revenue of $371,120 declined by 72.03% from the same period last year, which missed the estimate of $850,000.
Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 10, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2021/41181
Recent Stock Performance
52-week high: $33.79
Company's 52-week low was at $6.24
Price action over last quarter: down 33.23%
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.